Cyril Allouche, Principal Financial Officer at Revance Therapeutics, Inc. (RVNC), sold 393 shares at $28.35 ($11K) on 2018-07-06, disclosed to the SEC on 2018-07-06.
Scheduled sale ($11k) by Principal Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RVNC | SELL | 2019-01-04 | $7K | — | Filing → |
| RVNC | SELL | 2018-11-21 | $10K | — | Filing → |
| RVNC | SELL | 2018-11-09 | $104K | — | Filing → |